论文部分内容阅读
目的观察唑来膦酸联合VAD方案化疗治疗初治的多发性骨髓瘤(MM)骨痛的疗效及不良反应。方法选择54例MM患者随机分为两组,对照组26例,治疗组28例。对照组单用VAD方案化疗,治疗组接受唑来膦酸联合VAD化疗,比较两组的止痛疗效。结果对照组骨痛缓解显效2例,有效14例,总有效率61.54%。治疗组显效11例,有效14例,总有效率89.29%,两组总有效率比较差异有统计学意义(P<0.05)。治疗组3例、对照组2例出现恶心、食欲下降,治疗组2例出现发热。结论唑来膦酸联合VAD方案化疗治疗初治的MM骨痛,疗效确切,不良反应少,具有良好的耐受性。
Objective To observe the efficacy and adverse reactions of zoledronic acid combined with VAD regimen in the treatment of initially treated multiple myeloma (MM) bone pain. Methods 54 patients with MM were randomly divided into two groups, the control group of 26 patients, the treatment group of 28 patients. The control group was treated with VAD chemotherapy alone. The treatment group received zoledronic acid combined with VAD chemotherapy. The analgesic efficacy was compared between the two groups. Results In the control group, 2 cases of bone pain relief were relieved, 14 cases were effective, and the total effective rate was 61.54%. In the treatment group, 11 cases were markedly effective and 14 cases were effective. The total effective rate was 89.29%. There was significant difference between the two groups in total effective rate (P <0.05). Three patients in the treatment group and two patients in the control group showed nausea and loss of appetite. Two patients in the treatment group experienced fever. Conclusion Zoledronic acid combined with VAD regimen chemotherapy for treatment-naive MM bone pain has definite curative effect, few adverse reactions and good tolerability.